Leaderboards/PARP inhibition in cancer therapy

PARP inhibition in cancer therapy

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
B.J. Monk
Florida Cancer Specialists & Research Institute
2
Michalis Petropoulos
University of Bern
3
Léa Montégut
Icahn School of Medicine at Mount Sinai
4
Nagaraja Chappidi
University of Zurich
5
Carrie Printz
Unknown
6
Diana Zatreanu
Institute of Cancer Research
7
David Gallo
Hadassah Medical Center
8
Bingfeng Lu
Guangzhou Medical University
9
Juan A. Pérez-Bermejo
Fondazione GraphiTech
10
Edoardo José Longarini
Princeton University

Papers

1
Transcription–replication conflicts underlie sensitivity to PARP inhibitors
Nature|2024
181 cit.
2
Publication in Molecular Cancer (2024) [159 citations, W4397044051]
Molecular Cancer|2024
159 cit.
3
Publication in Cell (2024) [154 citations, W4391542423]
Cell|2024
154 cit.
4
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Annals of Oncology|2024
150 cit.
5
Publication in Nature Communications (2024) [49 citations, W4397033247]
Nature Communications|2024
49 cit.
6
LBA30 ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC)
Annals of Oncology|2024
35 cit.
7
Publication in Molecular Cancer (2024) [24 citations, W4402321108]
Molecular Cancer|2024
24 cit.
8
Publication in OncoImmunology (2024) [16 citations, W4403190877]
OncoImmunology|2024
16 cit.
9
Publication in Proceedings of the National Academy of Sciences (2025) [12 citations, W4412073672]
Proceedings of the National Academy of Sciences|2025
12 cit.
10
Functional screening in human HSPCs identifies optimized protein-based enhancers of Homology Directed Repair
Nature Communications|2024
6 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Michel Vulfovich
Memorial Healthcare System
2
Xiaoyang Su
Rutgers, The State University of New Jersey
3
Alex Sigal
Hebrew University of Jerusalem
4
Anthony R. Fehr
University of Kansas
5
Sarah Runswick
Allgemeine Gewerbeschule Basel
6
Zuzana Hořejšı́
Queen Mary University of London
7
Elaine Cadogan
AstraZeneca (Singapore)
8
Sophie Postel‐Vinay
Université Paris-Sud
9
Xiaochun Yu
Westlake University
10
Matthias Altmeyer
University of Zurich

Papers

1
SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape
Cell Host & Microbe|2022
241 cit.
2
Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
Nature Communications|2022
187 cit.
3
Folate Receptor Alpha—A Novel Approach to Cancer Therapy
International Journal of Molecular Sciences|2024
104 cit.
4
Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant
Nature Communications|2023
97 cit.
5
Omicron infection enhances Delta antibody immunity in vaccinated persons
Nature|2022
89 cit.
6
Phase separation properties of RPA combine high-affinity ssDNA binding with dynamic condensate functions at telomeres
Nature Structural & Molecular Biology|2023
81 cit.
7
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)
Journal for ImmunoTherapy of Cancer|2023
63 cit.
8
SARS-CoV-2 Mac1 is required for IFN antagonism and efficient virus replication in cell culture and in mice
Proceedings of the National Academy of Sciences|2023
61 cit.
9
Discovery of compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding by high-throughput screening
Antiviral Research|2022
36 cit.
10
Claudins in Cancer: A Current and Future Therapeutic Target
International Journal of Molecular Sciences|2024
36 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Alan Ashworth
University of California, San Francisco
2
Guy G. Poirier
Centre hospitalier universitaire de Québec
3
Thomas Helleday
Science for Life Laboratory
4
Ursula A. Matulonis
Dana-Farber Cancer Institute
5
Graeme C.M. Smith
Acacia Pharma (United Kingdom)
6
Nihal Ahmad
University of Wisconsin–Madison
7
Johann S. de Bono
Royal Marsden NHS Foundation Trust
8
Valina L. Dawson
Johns Hopkins University
9
Yves Pommier
National Cancer Institute
10
Ivan Ahel
University of Oxford

Papers

1
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Nature|2005
6.7k cit.
2
Dose translation from animal to human studies revisited
The FASEB Journal|2007
6.3k cit.
3
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Nature|2005
5.2k cit.
4
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
New England Journal of Medicine|2012
4.6k cit.
5
Abiraterone and Increased Survival in Metastatic Prostate Cancer
New England Journal of Medicine|2011
4.4k cit.
6
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers
New England Journal of Medicine|2009
3.6k cit.
7
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
The Lancet|2010
3.3k cit.
8
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
New England Journal of Medicine|2016
2.5k cit.
9
Olaparib for Metastatic Castration-Resistant Prostate Cancer
New England Journal of Medicine|2020
2.2k cit.
10
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
New England Journal of Medicine|2015
2.2k cit.

Reagents for PARP inhibition in cancer therapy

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

Cell Signaling Technology

OAS1 (D1W3A) Rabbit Monoclonal Antibody

Cited in 9 papers
#14498$157,348
View Evidence →

⭐ Top Rated

Best all-around

Santa Cruz Biotechnology

Rad51 (H-92)

Cited in 23 papers
#sc-8349
View Evidence →
Cell Signaling Technology

SignalStain® Proliferation/Apoptosis IHC Sampler Kit

Cited in 22 papers
#8109$686
View Evidence →
Proteintech

Geminin Polyclonal antibody

Cited in 18 papers
#10802-1-AP$449
View Evidence →

🌟 All-Time

Most validated

MedChemExpress

PI-103

Cited in 31 papers
#HY-10162
View Evidence →
Santa Cruz BiotechnologyEvidence 60

BRCA1 (D-9)

Cited in 28 papers
#sc-6954
View Evidence →
BethylEvidence 69

Rabbit anti-Phospho RPA32 (S4/S8) Antibody, Affinity Purified

Cited in 24 papers
#A300-245A (also A300-245A-M, A300-245A-T)
View Evidence →